Nanocopoeia is a drug delivery company with a nanotechnology enabled portfolio of dermal and transdermal therapeutic products. Our business model is to enhance the value and performance of off-patent, already-proven drugs by creating novel nanoformulations optimized for delivery into and through the skin. Our two lead products target the chronic, clinical conditions of pain and acne.

We differentiate our business by demonstrating the flexibility of our nanoformulation and skin delivery technology to speed improved versions of established drugs to market. The regulatory approval cycle and time to market for our products will be minimized by focusing on generic drugs in reformulated delivery versions that can be developed using FDA's 505(b)(2) pathway. This leverages prior investment by others in demonstrating the previously approved drug's safety and efficacy.

Nanocopoeia is seeking up to $10 million in a Series "A" round of financing to enable rapid development of these first two products in our development pipeline. A return on this investment is created through acquisition by pharmaceutical companies interested in our portfolio of formulated drugs and our formulation technology.

Download Executive Summary
Download Investor Presentation